Latest Close
$41.17
Stock Hub
VTVT
vTv Therapeutics Inc.
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
$23.68 (+135.39%)
Market Cap
$162,154,384.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
52W Range
$14.00 to $44.00
Target Mean Price
$53.33
Beta
0.40
Trailing P/E
Not available
Forward P/E
-11.06
Price / Book
7.93
Company Overview
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.